CLINICAL_TRIALS
ClinicalTrials.gov record update
Postponing or Omitting Re-irradiation After Tislelizumab Plus Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04921995
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:43.924581+00:00
- Published At
- 2022-04-04T00:00:00+00:00
- Record Updated At
- 2022-04-04
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Recurrent Nasopharyngeal Carcinoma", "Unresectable Nasopharyngeal Carcinoma", "Chemotherapy Effect", "Immunotherapy", "Stereotactic Body Radiation Therapy (SBRT)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-04-04"- protocolSection.identificationModule.nctId
"NCT04921995"- protocolSection.identificationModule.officialTitle
"Postponing or Omitting Re-irradiation After Tislelizumab Plus Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.